Leidos Holdings has awarded Pfenex a subcontract to develop a scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5). The contract follows successful preclinical studies performed by Leidos collaborators to evaluate the Rh5 antigen that was produced using the Pfēnex Expression Technology platform.   The subcontract is funded with federal funds from Leidos’ prime Malaria Vaccine Production an...